Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Access to branded medicines boosted by new drugs deal, says Hunt

GP access to branded medicines will improve under the latest drug price deal struck with the pharmaceutical industry, claims the health secretary.

Jeremy Hunt said the new five-year Pharmaceutical Price Regulation Scheme (PPRS) will help the NHS in ‘managing the cost’ of newer medicines and help the UK pharmaceutical industry to flourish.

It will freeze current spending on branded medicines for two years, followed by a less than 2% increase in the following three years – compared to an average increase of 5% each year under the previous contract.

In 2011/12 the NHS spent more than £12bn on branded medicines, the new contract will see costs above this level being ‘absorbed by the industry’.

A strengthening of statutory regulations, for companies who don’t sign up to the PPRS agreement, will force a 15% price cut on branded medicines to ensure ‘there are always safeguards in place for the NHS around the prices it pays for medicines’.

In a statement, health secretary Jeremy Hunt said: ‘This agreement ensures NHS patients will receive the best and most advanced medicines in the world while managing the cost. 

‘UK pharmaceutical companies have responded to the challenges we face as a country, both in terms of the increased demand for medicines and pressure on public spending. I hope in return we have given them the certainty and backing they need to flourish as a sector both here and in the global market.’

ABPI president, Deepak Khanna, said: ‘This has been a very challenging and long negotiation and it should not be underestimated how tough this deal is for the industry. However, we have agreed to play our part in recognising the financial challenges facing the NHS whilst focusing on the key issue of ensuring that patients in the UK get access to the medicines they need.’

Readers' comments (4)

  • I hope that this will allow more patients to receive drugs still under patent rather than increased use of branded products where a range of generics are available or it will be a wasted opportunity.

    Unsuitable or offensive? Report this comment

  • Sounds like the government is abusing it's position as the dominant purchaser in the UK pharmacy industry.

    It may be in the interests of the people, but if it were tesco or a private company driving this deal it would be criticised and possibly illegal.

    Unsuitable or offensive? Report this comment

  • This won't work the way they think it will. If pharma companies are not happy with their deal they will simply make a commercial decision to withdraw supply.

    Unsuitable or offensive? Report this comment

  • Money money money it's a rich mans world

    Unsuitable or offensive? Report this comment

Have your say